Earnings

Familiar names highlight Pfizer's Q2

Familiar names highlight Pfizer's Q2

By

Historical big earners once again performed for Pfizer in Q2, while Ibrance broke the $1 billion barrier.

Healthcare takes blame for disappointing Q2 for Publicis Groupe

Healthcare takes blame for disappointing Q2 for Publicis Groupe

The holding company has launched a review of its Publicis Health Solutions business after a volatile Q2.

Stelara highlights J&J's Q2 performance

Stelara highlights J&J's Q2 performance

The company posted a sales increase of 10.6% in the second quarter.

Omnicom healthcare revenue up 4.8% in Q2

Omnicom healthcare revenue up 4.8% in Q2

By

The holding company's overall revenue was up 1.8% in the period to $3.9 billion.

Innovative health gains highlight Pfizer's Q1

Innovative health gains highlight Pfizer's Q1

By

The unit was up 6% in the first quarter.

IPG CEO praises 'range of agencies' for Q1 revenue growth

IPG CEO praises 'range of agencies' for Q1 revenue growth

The strong start to 2018 means the firm is on track to hit financial targets for the year, said Michael Roth.

Five things for pharma marketers to know: Thursday, March 1, 2018

Five things for pharma marketers to know: Thursday, March 1, 2018

WPP segment including health and wellness outperforms rest of holding company in Q4; Novartis partners with Pear on app development; Study: 3 million-plus Americans could join association health plans in four years.

Interpublic Group's net income drops 4.8% but shares surge on strong Q4

Interpublic Group's net income drops 4.8% but shares surge on strong Q4

In 2017, Interpublic reported a net income of $579 million, down 4.8% from the previous year.

Five things for pharma marketers to know: Wednesday, February 14, 2018

Five things for pharma marketers to know: Wednesday, February 14, 2018

IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.

Five things for pharma marketers to know: Tuesday, February 6, 2018

Five things for pharma marketers to know: Tuesday, February 6, 2018

By

Allergan Q4 earnings beat estimates; Mars publishes research policies; Conway takes control of White House opioid agenda.

Five things for pharma marketers to know: Wednesday, January 24, 2018

Five things for pharma marketers to know: Wednesday, January 24, 2018

By

Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

By

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Five things for pharma marketers to know: Thursday, November 2, 2017

Five things for pharma marketers to know: Thursday, November 2, 2017

By

Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III

Analysts agree with WPP that threat from consultancies has been 'overhyped'

Analysts agree with WPP that threat from consultancies has been 'overhyped'

By

During its third quarter earnings call yesterday, WPP dismissed the threat from management consultants as "overhyped". Analysts concur.

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Thursday, October 26, 2017

Five things for pharma marketers to know: Thursday, October 26, 2017

By

Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug

Five things for pharma marketers to know: Wednesday, October 25, 2017

Five things for pharma marketers to know: Wednesday, October 25, 2017

By

FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs

Five things for pharma marketers to know: Tuesday, October 17, 2017

Five things for pharma marketers to know: Tuesday, October 17, 2017

By

J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing

Omnicom continues organic growth lead over rival ad networks

Omnicom continues organic growth lead over rival ad networks

By

By comparison, Omnicom's client roster includes less consumer goods companies compared to rivals WPP and Publicis Groupe.

Media is where agencies are hurting

Media is where agencies are hurting

By

Why is revenue growth at some of the agency groups lagging forecasts for global ad expenditure?

Analysts on WPP: 'expected bad, got worse'

Analysts on WPP: 'expected bad, got worse'

By

Business analysts have generally agreed that WPP's half-year earnings fell below expectations given recent market commentary, but have offered mixed guidance going forward.

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

By

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

By

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

J2 Global considers divesting parts of Everyday Health

J2 Global considers divesting parts of Everyday Health

By

The company acquired Everyday Health in December.